HANSEN Pharmaceutical Co., Ltd. (002412.SZ) Achieves Five‑Day Consecutive Record‑High Trading

Date: 2026‑08‑25Source: stock.eastmoney.com

Market Performance

  • Consecutive Gains: HANSEN Pharmaceutical closed at 11.21 CNY on 2026‑08‑25, matching its 52‑week high.
  • Five‑Day Rally: The shares logged a five‑day consecutive record of price increases, the most recent of which was a 5.32% rise from the previous day’s close.
  • Volume Context: The daily trading volume for the Shenzhen market was 1.83 trillion CNY, down by 1756 billion CNY from the prior day, indicating a broader market contraction while HANSEN maintained strong investor interest.

Sector and Market Dynamics

  • Innovation Drug Theme: HANSEN was among the top performers in the innovation‑drug sector, which saw a resurgence after a period of pullback. Other leading stocks in the same theme included Ke Lai Ying and Huai Sheng Pharma.
  • Concentration of Gains: Over 70 stocks reached the daily price‑limit on 2026‑08‑25. HANSEN’s five‑consecutive‑limit status placed it among the most resilient performers in the market.
  • Market Sentiment: Despite a slight rise in the Shanghai Composite Index (+0.19%) and a decline in the Shenzhen Component Index (‑0.35%), the market’s overall trading volume was reduced, suggesting a selective rally driven by high‑quality, sector‑specific stocks.

Company Fundamentals

  • Market Capitalization: 5.64 billion CNY.
  • Price‑Earnings Ratio: 22.77.
  • Product Portfolio: The company specializes in traditional Chinese medicinal preparations across digestive, cardiovascular, cerebrovascular, urological, traumatology, and diagnostic categories. Products are sold in multiple dosage forms, including injections, tablets, capsules, granules, syrups, decoctions, tinctures, and pills.
  • Historical Context: Founded in 1998 and headquartered in Yiyang, China, HANSEN has positioned itself as a key player in the traditional Chinese medicine (TCM) market domestically and abroad.

Implications

The five‑day consecutive limit‑price performance indicates sustained investor confidence in HANSEN’s product pipeline and market position within the TCM sector. Coupled with the broader sectoral rebound in innovation‑drug stocks, the company’s recent trading activity may signal a potential for further upside if market conditions remain supportive.